

Datasheet: HCA316P

BATCH NUMBER 157003

Description:	HUMAN ANTI RANIBIZUMAB:HRP
Specificity:	RANIBIZUMAB
Other names:	Lucentis
Format:	HRP
Product Type:	Monoclonal Antibody
Clone:	AbD29858_hIgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is conjugated to horseradish peroxidase (HRP) and supplied as liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	Antibody concentration 0.1 mg/ml
Immunogen	Ranibizumab

Specificity **Human Anti-Ranibizumab Antibody, clone AbD29858_hlgG1** is a non-inhibitory, anti-idiotypic antibody in full immunoglobulin format that specifically recognizes the monoclonal antibody drug ranibizumab and ranibizumab when in complex with recombinant human vascular endothelial growth factor A (VEGF-A). It does not recognize free human VEGF-A or bevacizumab. This antibody can be used to measure levels of free ranibizumab and biosimilars in patient samples.

Clone AbD29858_hlgG1 in full immunoglobulin format can be used to develop a pharmacokinetic (PK) antigen capture format assay to measure free ranibizumab that has been captured via immobilized VEGF-A.

Ranibizumab (Lucentis) is a humanized Fab fragment antibody (VH3-23/kappa1), originating from the same parental mouse antibody as bevacizumab (Avastin); it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab. Ranibizumab was first approved to treat wet age-related macular degeneration (AMD), a common form of age-related vision loss. It is also approved for the treatment of macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Ranibizumab inhibits angiogenesis by binding to VEGF-A, blocking its interaction with VEGF receptors on the surface of endothelial cells, and thus preventing the subsequent growth of new blood vessels.

[View a summary of all anti-ranibizumab antibodies](#)

Affinity The monovalent intrinsic affinity of AbD29858_hlgG1 was measured as $K_D=18$ nM by real time, label-free molecular interaction analysis on immobilized VEGF/ranibizumab complex.

ELISA Clone AbD29858_hlgG1 can be used in a direct or indirect ELISA on ranibizumab or as a detection reagent for free ranibizumab captured via immobilized VEGF-A.

Protocol: [PK antigen capture ELISA to measure free drug](#)

Storage Store at Store at -70°C.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee 12 months from date of despatch

Acknowledgements Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Lucentis is a trademark of Genentech.

Health And Safety Information Material Safety Datasheet documentation #10094 available at: <https://www.bio-rad-antibodies.com/SDS/HCA316P>
10094

Licensed Use For in vitro research purposes and for commercial applications for the provision of in vitro

testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#)

Related Products

Recommended Negative Controls

[RECOMBINANT HUMAN IgG1 LAMBDA ALLOTYPED G1m3 \(HCA049\)](#)

Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[RECOMBINANT HUMAN VEGF-A \(PHP293\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M371774:200612'

Printed on 12 Sep 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)